BioLineRx (NASDAQ/TASE: BLRX) announced today positive top-line results from BL-8040’s Phase 2 clinical trial in relapsed or refractory acute myeloid leukemia . Data also identify a potential biomarker for future selection of BL-8040-responsive AML patients
BioLineRx Announces Initiation of Phase 2 Trial for BL-8040 as Novel Stem Cell Mobilization Treatment
BioLineRx Ltd. (NASDAQ/TASE:BLRX) announced today the initiation of a Phase 2 trial for BL-8040 as a novel approach for the mobilization and collection of bone marrow stem cells from the peripheral blood circulation.
BioLineRx Announces Collaboration with MSD to investigate the combination of KEYTRUDA® (pembrolizumab) and BL-8040 in Pancreatic Cancer
BioLineRx Ltd. (NASDAQ/TASE: BLRX) today announced a collaboration with MSD, known as Merck in the US and Canada, to support a Phase 2 study investigating BioLineRx’s BL-8040 in combination with KEYTRUDA® (pembrolizumab), MSD’s anti-PD-1 therapy, in patients with metastatic pancreatic cancer.
Initiation of Phase 1/2 Trial for Novel Treatment in Two Bone Marrow Failure Conditions, hypoplastic myelodysplastic syndrome (hMDS) and aplastic anemia (AA) with BL8040
“BioLineRx Announces Initiation of Phase 1/2 Trial for Novel Treatment in Two Bone Marrow Failure Conditions
Efficacy and safety study, in collaboration with MD Anderson Cancer Center,
will assess BL-8040 as combination treatment with immunosuppressants
Interim results of study, in patients with hypoplastic myelodysplastic
syndrome (hMDS) and aplastic anemia (AA), expected by end of 2016″
“BioLineRx Announces Positive Clinical Results from First Part of Phase 2 Trial in r/r AML
– Data strongly suggest BL-8040 has potent anti-leukemic activity
in combination with Ara-C in AML “-
BioLineRx Announces Initiation of Phase 2b Trial for Novel AML Consolidation Treatment
Phase 2b study, as consolidation treatment for AML patients responding to standard induction treatment, will enroll up to 194 patients, randomized
in 1:1 ratio, at up to 25 sites in Germany
BioLineRx Presented Positive Safety and Efficacy Results for Novel Stem-Cell Mobilization Treatment with BL8040 at European Hematology Association Conference.
BL-8040’s rapid stem-cell mobilization supports stand-alone one-day treatment for stem-cell collection. Graft derived from BL-8040 treatment shows unique cell composition.
BioLineRx Initiated Expansion Stage of Phase 2 Clinical Trial for Novel Treatment for Acute Myeloid Leukemia.
BL-8040 remains safe and well tolerated at highest dose; continues to induce robust mobilization and leukemia cell death
BioLineRx Announces Regulatory Submission for Phase 2b Trial for Novel AML Consolidation Treatment . BL-8040 Phase 2b study, as consolidation treatment for AML patients responding to standard induction treatment, is expected to commence shortly after receipt of regulatory approval, anticipated in next few months.
Biokine Therapeutics Announces Issuance of European Patent covering the composition and use of novel chemokine binding polypeptides capable of inhibiting the course of autoimmunity, inflammation, and cancer (BKT130 project).